Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.

Abstract excerpt

BACKGROUND: Continuous venetoclax-azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite-duration VA could achieve comparable or superior efficacy to infinite-duration VA. Additionally, umbilical cord blood (UCB) transfusion improves clinical safety for elderly patients. Therefore, this single-center study...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Azacitidine
• Share to Bridged Bicyclo Compounds, Heterocyclic